comparemela.com

Latest Breaking News On - James vane tempest - Page 4 : comparemela.com

SARTORIUS VORZUEGE : Jefferies sticks Neutral -March 12, 2024 at 06:37 am EDT

James Vane-Tempest from Jefferies retains his Neutral opinion on the stock. Previously set at EUR 313, the target price has been raised to EUR 359.

James-vane-tempest

SARTORIUS STEDIM BIOTECH : Jefferies remains its Buy rating -March 12, 2024 at 06:39 am EDT

Already positive, the research from Jefferies and its analyst James Vane-Tempest still consider the stock as a Buy opportunity. The target price is revised upwards from EUR 330 to EUR 286.

James-vane-tempest
Markets

SCHOTT PHARMA : Jefferies sticks Neutral -February 29, 2024 at 04:09 am EST

In a research note, Jefferies analyst James Vane-Tempest has maintained his recommendation on the stock with a Neutral rating. The target price remains unchanged at EUR 34.30.

James-vane-tempest

Gerresheimer Shares Rise on Upbeat Outlook, Booming Obesity-Drug Demand

By Nina Kienle Gerresheimer shares rose after the company gave a better-than-expected revenue outlook for 2025 and said it secured new orders related to.

Germany
German
Nina-kienle
James-vane-tempest
Article-normal
Pharmaceuticals
Healthcare-life-sciences
Financial-performance
Share-price-movement-disruptions
Corporate-industrial-news
Equity-markets

FRESENIUS SE : Jefferies reiterates its Buy rating -February 21, 2024 at 03:25 am EST

In a research note published by James Vane-Tempest, Jefferies advises its customers to buy the stock. The target price is still set at EUR 41.

James-vane-tempest
Markets

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.